NCT02505191已完成1 期
A Pilot Phase I, Randomised, Open Mono-center, Multiple Dose, Two Parallel Groups Clinical Trial Investigating the Pharmacokinetics of a Prolonged-release Formulation in Comparison to an Immediate-release Formulation of St. John's Wort Extract Ze 117 in Healthy Male Volunteers Under Fasting Condition
Max Zeller Soehne AG1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2015年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Half Value Duration (HVD) of surrogate markers of the total extract Ze 117
研究概览
简要总结
A pilot phase I, randomised, open mono-center, two parallel group clinical trial investigating the pharmacokinetics of a prolonged-release formulation in comparison to an immediate-release formulation of St. John's wort extract Ze 117 in healthy male volunteers under fasting condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Caucasian male volunteers
- •Physically and mentally healthy as judged by means of a medical and standard laboratory examination
- •BMI of between 19 and 29 kg/m2, inclusively
- •Weight not exceeding 90 kg
- •Non-smokers (confirmed by urine cotinine test)
- •Informed cConsent as documented by signature
排除标准
- •Known or suspected hypersensitivity to any ingredient of the investigational medicinal product
- •Any clinically significant illnesses or clinically significant surgery within 1 year prior to the administration of the study medication
- •Any surgical or medical condition which might interfere with absorption, distribution, metabolism or excretion of the drug
- •Any clinically significant abnormality or abnormal laboratory test results, as judged by the investigator found during the medical screening
- •Positive test of hepatitis B, hepatitis C or HIV screening (HIV antibody, Hepatitis B (HBsAg), Hepatitis C (HCV)
- •ECG abnormalities (clinical significant) or vital signs abnormalities (systolic blood pressure lower than 90 or over 145 mmHg, diastolic blood pressure lower than 60 or over 95 mmHg, or heart rate less than 45 or over 100bpm) at screening
- •History of asthma or obstructive pulmonary disease (e.g.COPD)
- •Known photohypersensitivity.
- •Presents or history of alcohol dependence within the last year (> 40 g ethanol/d or more than 10 units per weeks (1unit=150 ml of wine or 360 ml of beer or 45 ml alcohol 45%))
- •History of drug dependence or positive results of drug screen
- •Concomitant participation in another clinical trial within the 4 weeks prior to the planned first drug administration.
- •Donation of blood or blood products within 30 days prior to the planned first drug administration.
- •Treatment with any medication or topical drugs with systemic action used in the past 4 weeks, prior to the planned first drug administration ,or 6 times the half-life of the respective drug, whatever is longer (excluding single use of paracetamol or ibuprofen up to 24 hours prior to the planned first drug administration).
- •Suspected inability, e.g. language problems, or known or suspected non-compliance, e.g. non-willingness to fulfil the dietary restrictions
- •Difficulty to swallow study medication
- •Enrolment of the investigator, his/her family members, employees and other dependent persons
- •Any reason which, in the opinion of the Investigator, would prevent the subject from participating the study
研究组 & 干预措施
Test
Experimental
St. John's wort prolonged-release tablet 500 mg
干预措施: St. John's wort prolonged-release tablet 500 mg (Drug)
Reference
Active Comparator
St. John's wort film coated tablets 250 mg (Remotiv N)
干预措施: St. John's wort film coated tablets 250 mg (Drug)
结局指标
主要结局
Half Value Duration (HVD) of surrogate markers of the total extract Ze 117
时间窗: 3 days
次要结局
- Tmax of surrogate markers of the total extract Ze 117(3 days)
- AUCss of surrogate markers of the total extract Ze 117(3 days)
- Cmax of surrogate markers of the total extract Ze 117(3 days)
- Cmin of surrogate markers of the total extract Ze 117(3 days)
- lag time of surrogate markers of the total extract Ze 117(3 days)
- T1/2 of surrogate markers of the total extract Ze 117(3 days)
- Peak-trough fluctuation (PTF) of surrogate markers of the total extract Ze 117(3 days)
- Mean Residence Time (MRT) of surrogate markers of the total extract Ze 117(3 days)
- Half value Duration (HVD) of hyperforin(3 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment SubjectsMyelofibrosisNCT06598956Chia Tai Tianqing Pharmaceutical Group Co., Ltd.32
已完成
1 期
To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment SubjectsMulti-resistant Gram-negative Bacteria Cause InfectionNCT06522945Chia Tai Tianqing Pharmaceutical Group Co., Ltd.48
已完成
1 期
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male SubjectsHealthy Male SubjectsNCT04512872Celltrion30
招募中
1 期
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.Β-thalassemiaNCT06655662Shenzhen Hemogen8
已完成
1 期
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative ColitisUlcerative Colitis (Part 2 Only)Crohn's DiseaseNCT02883452Celltrion181